A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisAlena Novotná, Jan Mareš, S. Ratcliffe et al.|European Journal of Neurology|2011Cited by 465
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and ProgressionMarianna Cortese, Tuula Pirttilä, Xavier Montalbán et al.|Neurology|2025Cited by 3